EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Age Is Just a Number: Progress and Obstacles in the Discovery of New Candidate Drugs for Sarcopenia

Hyun-Jun Kim iD, Da-Woon Jung, Darren Reece Williams iD

Cells · 11.11.2023 · 12 (22) · 2608

DOI: 10.3390/cells12222608 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 11.11.2023. Verfasst von Hyun-Jun Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: New Drug Targets Laboratory, School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea. Hauptthemen laut MEDLINE: Sarcopenia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 205 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korean government (MSIT), GIST.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sarcopenia is a disease characterized by the progressive loss of skeletal muscle mass and function that occurs with aging. The progression of sarcopenia is correlated with the onset of physical disability, the inability to live independently, and increased mortality. Due to global increases in lifespan and demographic aging in developed countries, sarcopenia has become a major socioeconomic burden. Clinical therapies for sarcopenia are based on physical therapy and nutritional support, although these may suffer from low adherence and variable outcomes. There are currently no clinically approved drugs for sarcopenia. Consequently, there is a large amount of pre-clinical research focusing on discovering new candidate drugs and novel targets. In this review, recent progress in this research will be discussed, along with the challenges that may preclude successful translational research in the clinic. The types of drugs examined include mitochondria-targeting compounds, anti-diabetes agents, small molecules that target non-coding RNAs, protein therapeutics, natural products, and repositioning candidates. In light of the large number of drugs and targets being reported, it can be envisioned that clinically approved pharmaceuticals to prevent the progression or even mitigate sarcopenia may be within reach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcopeniaHumansMuscle, SkeletalAgingLongevityMitochondria

Stichwörter der Autor:innen

agingdrug discoverysarcopeniaskeletal muscle

Autor:innen und Institutionen

  • New Drug Targets Laboratory, School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea.

ORCID-Profile: Hyun-Jun Kim, Darren Reece Williams

Förderung

  • National Research Foundation of Korea
  • Korean government (MSIT)
  • GIST

Zitieren

APA

Kim, H. J., Jung, D. W., & Williams, D. R. (2023). Age Is Just a Number: Progress and Obstacles in the Discovery of New Candidate Drugs for Sarcopenia. Cells, 12(22), 2608. https://doi.org/10.3390/cells12222608

Vancouver

Kim HJ, Jung DW, Williams DR. Age Is Just a Number: Progress and Obstacles in the Discovery of New Candidate Drugs for Sarcopenia. Cells. 2023;12(22):2608. doi:10.3390/cells12222608

BibTeX
@article{Kim2023,
  author = {Kim, Hyun-Jun and Jung, Da-Woon and Williams, Darren Reece},
  title = {Age Is Just a Number: Progress and Obstacles in the Discovery of New Candidate Drugs for Sarcopenia},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {22},
  pages = {2608},
  doi = {10.3390/cells12222608}
}
Kostenlos starten →